The emergence of methemoglobinemia amidst the COVID-19 pandemic

To the Editor:
Coronavirus disease 2019 (COVID-19) has been associated with a range of hematologic findings and complications [1]. We have encountered three cases of significant methemoglobinemia, and five cases of relatively mild methemoglobinemia, among patients being treated for COVID-19 in our health system during a 4 week period in April 2020. For comparison, there was only one case of mild acquired methemoglobinemia of any cause documented in our health system during the preceding year. Below we describe the three cases of significant methemoglobinemia, including their presentations, treatments, and outcomes.

Case 1: A 50 year-old man with no medical history presented with acute hypoxic respiratory failure (AHRF) due to COVID-19. He received hydroxychloroquine on hospital day (HD) 1, and continued through HD5. He also received brief courses of azithromycin and ceftriaxone. He deteriorated quickly, requiring intubation and mechanical ventilation on HD2, initiation of vasopressors on HD3, and renal replacement therapy on HD4. Persistently low oxygen saturation on pulse oximetry, despite mechanical ventilation with 100% FIO2, prompted blood co-oximetry, which demonstrated a Met-Hb level of 22%. The patient received methylene blue 1 mg/kg and then 2 mg/kg as well as concurrent ascorbic acid, however his Met-Hb level increased to > 30%. He therefore received red cell exchange on HD9 with prompt improvement in his Met-Hb level (to 2.9%) and his oxygenation. He was continued on ascorbic acid for several days thereafter until complete normalization of his Met-Hb level. The patient remains critically ill and although he is no longer requiring vasopressors, he remains intubated and dialysis dependent.

Case 2: A 52 year-old man with history of morbid obesity and uncomplicated diabetes mellitus was admitted for AHRF due to COVID-19 infection. He was started on azithromycin on HD1 and hydroxychloroquine on HD2. He required intubation for worsening respiratory failure on HD4, however demonstrated persistent hypoxia despite mechanical ventilation with FIO2 of 100%. This prompted blood co-oximetry which demonstrated a Met-Hb level of 13.7%. Concurrently, he was noted to have evidence of Coombs-negative hemolysis. He received 1.8 mg/kg of methylene blue however his Met-Hb increased further to 18.8%, and laboratory studies indicated worsening hemolysis as well as a new diagnosis of G6PD deficiency. The patient passed away shortly thereafter.

Case 3: A 54 year-old man with a history of uncomplicated diabetes mellitus was admitted for AHRF due to COVID-19 infection. He required intubation on HD2 and mechanical ventilation or dialysis, he remains hospitalized. The patient was noted to have evidence of methemoglobinemia at presentation, which was confirmed by blood co-oximetry. The patient received methylene blue 1 mg/kg and then 2 mg/kg as well as concurrent ascorbic acid, however his Met-Hb level increased to > 30%. He therefore received red cell exchange on HD9 with prompt improvement in his Met-Hb level (to 2.9%) and his oxygenation. He was continued on ascorbic acid for several days thereafter until complete normalization of his Met-Hb level. The patient remains critically ill and although he is no longer requiring vasopressors, he remains intubated and dialysis dependent.

Methemoglobinemia occurs when iron in the porphyrin group of heme is oxidized from the ferrous (Fe2⁺) to the ferric (Fe3⁺) form [2]. Ferric heme binds oxygen irreversibly resulting in a left shift of the oxygen-hemoglobin dissociation curve. Methemoglobinemia is most often acquired, predominantly due to oxidizing medications. Antimalarial agents including chloroquine have been associated with methemoglobinemia, albeit rarely [3]. Although seemingly of less oxidizing potential than chloroquine, it is possible that the dramatic increase in use of hydroxychloroquine amidst the COVID-19 pandemic is now making this complication more common. This is likely exacerbated by the degree of critical illness among many COVID-19 patients, which puts them under greater oxidative stress, leaving them more susceptible to medication-induced methemoglobinemia. All three patients with significant methemoglobinemia discussed above received hydroxychloroquine, as did all five patients with relatively mild Met-Hb elevations (3% - 7%) encountered during this time period. The only other drug frequently used among this patient cohort was azithromycin, which is not known to be an oxidizing agent. Additionally, all patients in this series (including the three with significant Met-Hb elevation presented above, and the five with milder elevations) were already severely ill prior to initiation of hydroxychloroquine, and thus likely under oxidative stress even before the initiation of any medications. It is unclear if any additional properties of COVID-19, besides inducing oxidative stress during severe illness, might predispose to...
The first case of acquired hemophilia A associated with SARS-CoV-2 infection

To the Editor:
Acquired hemophilia A (AHA) is a rare bleeding disorder caused by circulating autoantibodies directed against clotting factor VIII (FVIII).1,2 It involves more frequently elderly people with no previous personal or family history of bleeding. Approximately half of patients with AHA do not have underlying or predisposing disorders (idiopathic cases), with the remaining cases being associated with a wide array of conditions or diseases (ie, post-partum, autoimmune and dermatologic disorders, malignancies, infections and drugs).3 In more than 80% of cases AHA is characterized by hemorrhage into the skin, muscles, soft tissues and mucous membranes (eg, epistaxis, gastrointestinal and urological bleeds, retroperitoneal hematomas).3 We present here the case of a 66-year-old man, who in November 2011 presented to the emergency room of the Mantua city hospital with spontaneous severe cutaneous and muscle bleeding. He had no history of bleeding. Blood tests revealed normocytic anemia (hemoglobin 9 g/dL) with normal white cell and platelet count and a prolonged activated partial-thromboplastin time (aPTT) (ratio 2.97, normal range 0.82-1.18) with normal prothrombin time. A mixing study resulted in failure of aPTT correction, suggesting the presence of an inhibitor that was successfully identified as directed against FVIII (FVIII activity <1%, inhibitor titer 25 Bethesda units [BU]). The diagnosis of idiopathic AHA was made. The patient was successfully treated with intravenous recombinant activated factor VII (90 μg/kg every 3 hours until bleeding stopped) and oral prednisone and cyclophosphamide (1 mg/kg/day for 4 weeks, then gradually tapered) with a complete remission (CR) achieved on day +21. Following a 9-year period of well-being with normal coagulation checks performed every 6 months, the patient was re-admitted to the Mantua city Hospital on March 2020 because of fever (38.7°C), cough, asthenia and difficulty breathing for 3 days. The diagnosis of Coronavirus Disease 2019 (COVID-19) was confirmed by RT-PCR in nasal swab. A chest CT scan showed a bilateral interstitial pneumonia. Due to the concomitant presence of an extensive hematoma in the trunk, an aPTT was performed and resulted prolonged (ratio 2.87). The diagnosis of AHA was

REFERENCES
1. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020. https://doi.org/10.1002/ajh.25829.
2. Cortazzo JA, Lichtman AD. Methemoglobinemia: a review and recommendations for management. J Cardiothorac Vasc Anesth. 2014;28(4):1043-1047.
3. Cohen RJ, Sachs JR, Wicker DJ, Conrad ME. Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N Engl J Med. 1968; 279(21):1127-1131.
4. Mansouri A, Lurie AA. Concise review: methemoglobinemia. Am J Hematol. 1993;42(1):7-12.

Received: 8 May 2020 Accepted: 8 May 2020
DOI: 10.1002/ajh.25865